0.7000SEK0.00%Mkt Cap: 41.31M SEKP/E: —Last update: 2026-05-13
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleaso…
Industry Peers
Diagnostics & Researchloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-6.98
PEG—
P/B1.56
P/S69.55
EV/EBITDA-0.88
EV/Revenue54.29
EPS (TTM)-1.32
EPS (Forward)-0.10
Cash Flow & Leverage
FCF Yield-48.09%
FCF Margin-3344.72%
Operating CF-23.80M SEK
CapEx (TTM)13.44M SEK
Net Debt/EBITDA0.25
Net Debt-9.07M SEK
Technical
SMA 500.8563 (-18.3%)
SMA 2000.8007 (-12.6%)
Beta1.52
S&P 52W Chg24.23%
Avg Vol (30d)110.36K
Avg Vol (10d)100.33K
Technical Indicators
RSI (14)39.5
MACD-0.0540
MACD Signal-0.0548
MACD Hist.+0.0008
BB Upper0.8772 SEK
BB Middle0.7655 SEK
BB Lower0.6538 SEK
BB Width29.18%
ATR (14)0.0966 SEK
Vol Ratio (20d)0.97x
52W Range
0.280013% of range3.560
52W High3.560 SEK
52W Low0.2800 SEK
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin-7492.09%
Oper. Margin-5423.28%
ROE-167.75%
ROA-87.50%
Revenue Growth-26.00%
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio0.44
Quick Ratio0.43
Book Value/Sh0.4480 SEK
Cash/Share0.1530 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:1000
Split DateOct 31, 2024
Ownership
Shares Out.59.19M
Float56.05M
Insiders28.84%
Institutions0.00%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap41.31M SEK
Enterprise Value32.25M SEK
Revenue (TTM)594.00K SEK
Gross Profit594.00K SEK
Net Income (TTM)-44.50M SEK
Revenue/Share0.0180 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees6
Last Price0.7000 SEK
CountrySE
SectorHealthcare
IndustryDiagnostics & Research
ISIN—